stockrow
Friday 6 November 2026
Export ADVB’s income statement to Excel — free account
Advanced Biomed Inc.
ADVB Healthcare Diagnostics & Research
Advanced Biomed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $127,600.00.
- EPS
- +174.2%
- Free cash flow
- −101.3%
Quarter to June 2026, against a year earlier
1.95
0.15
−7.14%
Follow ADVB
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to June
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 0 | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | 100.00 | — | ||||||
| EBT | — | — | — | — | — | — | — | (3) | (1) | (6) | +50.0% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | 0.00 | (4,907.92) | (4,907.9) pt | ||||||
| Net income | — | — | — | — | — | — | — | (3) | (3) | 7 | n/m | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.10 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | (2.78) | (3.20) | 5.33 | n/m | ||||||
| Cash flow | — | — | — | — | — | — | — | (2.13) | (5.68) | (1.55) | (14.5%) | ||||||
| Capex | — | — | — | — | — | — | — | (0.07) | (0.03) | (2.06) | +427.3% | ||||||
| Free cash flow | — | — | — | — | — | — | — | (2.20) | (5.71) | (3.61) | +28.2% | ||||||
| Book value | — | — | — | — | — | — | — | 1.66 | 3.39 | 9.80 | +142.7% | ||||||
| Shares, m | — | — | — | — | — | — | — | 1 | 1 | 1 | +11.9% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.79 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | 0.00 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | 0.47 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | (1.20) | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (2) | (6) | (2) | (4.3%) | |||||
| Capex | — | — | — | — | — | — | — | 0 | 0 | (3) | +490.3% | ||||||
| Free cash flow | — | — | — | — | — | — | — | (2) | (6) | (5) | +43.5% | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 0 | 3 | 12 | +520.7% | |||||
| Net debt | — | — | — | — | — | — | — | (3) | 0 | 0 | (61.6%) | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | 2 | 3 | 12 | +171.7% | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (23.86) | 36.47 | +36.5 pt | |||||
| ROIC | — | — | — | — | — | — | — | 0.00 | (19.70) | (32.76) | (32.8) pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | (126.79) | 84.77 | +84.8 pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 40 | 31 | 18 | (32.9%) | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.01 | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Jun 2026 · fundamentals updated 2 Nov 2026
Advanced Biomed Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NDRA ENDRA Life Sciences Inc. | $7.5M | — (loss-making) | — (loss-making) | −98.80% (below 0%: shrinking) | n/m | +15.04% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TTOO T2 Biosystems, Inc. | $6.5M | — (loss-making) | — (loss-making) | +34.85% (above 0%: growing) | n/m | +53.36% (above 0%: growing) | (106.60%) | (511.89%) | Compare |
| XWEL XWELL, Inc. | $6.1M | — (loss-making) | — (loss-making) | −7.08% (below 0%: shrinking) | n/m | −43.02% (below 0%: shrinking) | 41.26% | (29.45%) | Compare |
| BIAF bioAffinity Technologies, Inc. | $3.3M | — (loss-making) | — (loss-making) | +18.99% (above 0%: growing) | n/m | −23.69% (below 0%: shrinking) | 27.98% | (220.77%) | Compare |
| DMTKQ DermTech, Inc. | $3.3M | — (loss-making) | — (loss-making) | +10.58% (above 0%: growing) | n/m | +24.87% (above 0%: growing) | 18.54% | (533.37%) | Compare |
| ADVB Advanced Biomed Inc. | $3.1M | 0.3× | — | — | n/m | −101.33% (below 0%: shrinking) | — | 0.00% | |
| AWHL Aspira Women's Health Inc. | $2.4M | — (loss-making) | — (loss-making) | −14.89% (below 0%: shrinking) | n/m | −24.57% (below 0%: shrinking) | 55.28% | (89.69%) | Compare |
| ISPC iSpecimen Inc. | $2.0M | — (loss-making) | — (loss-making) | −78.70% (below 0%: shrinking) | n/m | −257.73% (below 0%: shrinking) | 45.23% | (897.30%) | Compare |
| PRPH ProPhase Labs, Inc. | $1.2M | — (loss-making) | — (loss-making) | −18.93% (below 0%: shrinking) | n/m | +56.67% (above 0%: growing) | 22.35% | (261.62%) | Compare |
| Median of peers | $3.3M | — | — | −10.98% | — | −4.32% | 25.17% | (241.19%) |
Pay and ownership Proxy statement filed 4 June 2026
Ownership
Directors and executive officers, together
27.01%
Yi Lu, Ph.D. (Fomer Chief Executive Officer)
20.30%
Xiaomin Chen (Chief Executive Officer)
16.34%
Hung To Pau (Director)
10.67%
Advance On Ventures Limited
6.61%
Wang Jie
6.05%
Yimin Jin
6.05%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement